Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections
Journal article, 2022
In this post-hoc analysis of data from a randomised clinical trial, we compared the effect of liraglutide to placebo on markers of insulin secretion in persons with type 2 diabetes treated with multiple daily insulin injections. Liraglutide increased insulin secretion, measured by C-peptide, by 19% after 24 weeks of treatment.
Clinical trial registration: EudraCT 2012-001941-42.
GLP-1 analogues
Multiple daily insulin injections
Insulin secretion
Type 2 diabetes mellitus
Author
Klara Westman
University of Gothenburg
NU Hospital Group
Henrik Imberg
Statistiska Konsultgruppen
Chalmers, Mathematical Sciences, Applied Mathematics and Statistics
Magnus O. Wijkman
Linköping University
Irl B. Hirsch
School of Medicine
J. Tuomilehto
University of Helsinki
National Institute for Health and Welfare
King Abdulaziz University
S. Dahlqvist
University of Gothenburg
NU Hospital Group
Marcus Lind
University of Gothenburg
NU Hospital Group
Journal of Diabetes and its Complications
1056-8727 (ISSN) 1873460x (eISSN)
Vol. 36 3 108110Subject Categories
Endocrinology and Diabetes
Other Clinical Medicine
Neurology
DOI
10.1016/j.jdiacomp.2021.108110
PubMed
35101325